iCAD (NASDAQ:ICAD) Raised to Hold at StockNews.com

iCAD (NASDAQ:ICAD) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Thursday.

iCAD Stock Performance

Shares of NASDAQ:ICAD opened at $3.03 on Thursday. iCAD has a 52-week low of $1.18 and a 52-week high of $3.78. The firm has a fifty day moving average of $2.44 and a 200 day moving average of $1.93. The firm has a market capitalization of $80.42 million, a PE ratio of -23.31 and a beta of 1.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Eagle Investment Management LLC grew its position in iCAD by 6.1% in the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock worth $1,311,000 after acquiring an additional 41,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in iCAD by 6.6% in the fourth quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company’s stock worth $506,000 after purchasing an additional 17,059 shares during the last quarter. Perritt Capital Management Inc lifted its stake in iCAD by 1.9% in the fourth quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company’s stock worth $346,000 after purchasing an additional 3,600 shares during the last quarter. Summit Trail Advisors LLC bought a new stake in iCAD in the fourth quarter worth $214,000. Finally, Granahan Investment Management LLC bought a new stake in iCAD in the fourth quarter worth $96,000. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.